Bexotegrast

bexotegrast

Phase 3

Sponsor: Pliant Therapeutics

Indication: IPF

Mechanism of Action

Dual integrin αvβ6 / αvβ1 inhibitor

Target: Integrin αvβ6, Integrin αvβ1

Clinical Information

Clinical Trials (ClinicalTrials.gov)

TERMINATEDNCT06097260

Phase:PHASE2Org:Pliant Therapeutics, Inc.

Relevant Publications (PubMed)

No recent publications found for bexotegrast.

Validated Models

This drug has been validated in the following preclinical models: